Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Depreciation & Amortization (CF) (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Depreciation & Amortization (CF) for 6 consecutive years, with $723000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) rose 1.69% to $723000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, down 30.23% year-over-year, with the annual reading at $2.9 million for FY2025, 29.27% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $723000.0 at TScan Therapeutics, down from $767000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $1.5 million in Q1 2023, with the low at $469000.0 in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.0 million, with a median of $1.1 million recorded in 2021.
  • The sharpest move saw Depreciation & Amortization (CF) soared 205.2% in 2021, then crashed 45.93% in 2025.
  • Over 5 years, Depreciation & Amortization (CF) stood at $1.1 million in 2021, then increased by 29.95% to $1.5 million in 2022, then dropped by 13.75% to $1.3 million in 2023, then tumbled by 44.45% to $711000.0 in 2024, then increased by 1.69% to $723000.0 in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $723000.0, $767000.0, and $698000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.